Clinical trial
Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
NCT00149734 · University of Colorado, Denver, Other · Completed
Key facts
| NCT number | NCT00149734 |
|---|---|
| Title | Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia |
| Official title | Atypical Antipsychotics and P50 Sensory Gating |
| Lead sponsor | University of Colorado, Denver, Other |
| Collaborators | National Institute of Mental Health (NIMH) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Ondansetron followed by placebo, Placebo followed by Ondansetron |
| Enrollment | 8 |
| Start date | Jan 1, 2005 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Sep 8, 2005 |
| Last update posted | Aug 13, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: